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Background: Recent studies observed that altered energy metabolism has become widespread in cancer cells
along with other cancer-associated traits that have been accepted as hallmarks of cancer. Akt signaling pathway is
involved in the aerobic glycolysis program. However, mechanisms underlying the regulation of aerobic glycolysis
and Akt activity in gliomas remain unclear. MicroRNAs are a group of small non-coding RNAs that can function as
endogenous RNA interference to regulate expression of targeted genes. This study was conducted to detect the
function of miR-7 targeting insulin-like growth factor 1 receptor (IGF-1R), which is an upstream regulator of Akt.
Methods: MicroRNA expression data for gliomas and normal controls were downloaded from The Cancer Genome
Atlas (TCGA) database. Quantitative real-time PCR was used to measure the microRNA-7 (miR-7) expression level,
and Western blot was performed to detect protein expression in U87 and U251 cells. Colony formation assay and
glycolysis stress test were also conducted. Luciferase reporter assay was used to identify the mechanism of IGF-1R
and miR-7 regulation.
Results: miR-7 was downregulated in human glioma tissues based on TCGA database. Forced expression of miR-7 or
IGF-1R knockdown inhibited colony formation and glucose metabolic capabilities of glioma cells in vitro and decreased
the p-Akt expression level. Bioinformatics analysis results indicated that IGF-1R could be a target of miR-7. Western blot
and luciferase reporter assays showed that miR-7 modulated IGF-1R expression by directly targeting the binding site
within the 3′-untranslated region.
Conclusions: This study provides the first evidence that miR-7 inhibits cellular growth and glucose metabolism in
gliomas, at least partially, by regulating the IGF-1R/Akt signaling pathway. Therefore, miR-7 is a promising molecular
drug for glioma treatment.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_211
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Malignant glioma is the most common and lethal pri-
mary brain tumor in adults. The fatal nature of malignant
gliomas is ascribed to their extensive cell proliferation,
intense resistance to cell apoptosis, and widespread infil-
tration throughout the brain. Despite multimodal therap-
ies, such as surgery, radiotherapy, and chemotherapy, the* Correspondence: jingdehua1963@163.com
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unless otherwise stated.median survival of glioblastoma multiforme (GBM) is less
than one year [1]. Novel therapeutic approaches are
required to improve long-term survival for this cancer.
Recent advances in our understanding of the biological
features of glioma offer opportunities for the design of a
new therapeutic strategy based on targeting essential sig-
naling pathways.
Altered energy metabolism is widespread in cancer
cells along with other cancer-associated traits that have
been accepted as hallmarks of cancer [2]. Otto Warburg
first observed an anomalous characteristic of cancer celltd. This is an Open Access article distributed under the terms of the Creative
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cer cells can reprogram their glucose metabolism and
consequently energy production by limiting their energy
metabolism to glycolysis. Such phenomenon is called
“aerobic glycolysis.” Increased glycolysis in cancer tissues
allows diversion of glycolytic intermediates into various
biosynthetic pathways that can synthesize macromole-
cules and organelles, which are required for assembling
new cancer cells [2-4]. Akt may constitute a “Warburg
kinase” that can be specifically targeted to alter cancer
cell energy metabolism for therapeutic benefits as sug-
gested in previous studies. Akt-induced glycolysis can be
mediated by multiple non-exclusive mechanisms, includ-
ing expression and membrane translocation of glucose
transporters. Akt-induced glycolysis can affect hexokinase
expression, activity, and mitochondrial interaction. Akt
may also indirectly activate the important rate-controlling
enzyme phosphofructokinase-1 (PFK1) by directly phos-
phorylating and activating phosphofructokinase-2 (PFK2)
[5]. The principal reaction product of PFK2, i.e., fructose-
2, 6-bisphosphate, is the most potent allosteric activator of
PFK1. Suppression of glycolytic gene expression by the
transcription factor FoxO could be reversed through
phosphorylation and inactivation by hyperactive Akt [6].
Akt hyperactivity can increase mTORC1 activity, thereby
increasing HIF1α abundance and expression of HIF1α-
associated glycolytic enzyme and Glc transporter [7].
Many recent studies demonstrated that dysregulation of
a tumor-related microRNA (miRNA) network serves a
critical function in glioma development and progression.
This network includes miR-181, miR-221/222, miR-21,
miR-124, miR-566, and miR-145 [8-14]. Lu also reported
that miR-7 exhibits low expression compared with that in
normal brain tissues [15]. miR-7 inhibits viability, inva-
siveness, and metastasis in glioma cells. A previous study
showed that some important functional molecules, such
as epidermal growth factor receptor (EGFR) and focal ad-
hesion kinase, are the direct target genes of miR-7 [16,17].
In this study, we used miRNA expression data down-
loaded from The Cancer Genome Atlas (TCGA) database
to examine the effects of miR-7 expression. We confirmed
that miR-7 served a critical function in cellular growth
and metabolism by directly targeting insulin-like growth
factor 1 receptor (IGF-1R), which is an upstream regulator
of Akt [18,19].
Methods
Microarray analysis and cell cultures
MicroRNA expression data for 480 glioma tissues and
10 normal brain tissues were downloaded from TCGA
database, and all 480 glioma cases involved GBM
(http://cancergenome.nih.gov). All specimens were col-
lected using institutional review board–approved proto-
cols [20]. Human glioma U87 and U251 are tworepresentative cell lines of human GBM; both of these cell
lines characterize the consequences of frequent PTEN-null
and EGFR overexpression [21]. The U87 and U251 cell
lines were purchased from the Chinese Academy of Sci-
ences Cell Bank. All cells were cultured in high-glucose
Dulbecco’s modified Eagle’s medium (DMEM; Gibco Cor-
poration, USA) supplemented with 10% fetal calf serum
(Hyclone, USA) at 37°C in a humidified atmosphere con-
taining 5% CO2. This study was approved by the Research
Ethics Committee of Xuzhou Central Hospital, China.
Cell transfection
All miRNA mimics were chemically synthesized and puri-
fied by GenePharma (Shanghai, China) based on the
following sequences: has-miR-7 mimic: 5′-UGGAAGAC
UAGUGAUUUUGUUGU-3′, miR-negative control (miR-
NC):5′-UUCUCCGAACGUGUCCGGAGAATT-3′. IGF-
1R and control siRNA oligonucleotide duplexes were
chemically synthesized by Invitrogen (si-IGF-1R: sense 5′-
CAACAGUGGUCAUCAUGGAACUGAUdTdT-3′, con-
trol siRNA (si-NC): sense 5′-UUCUCCGAACGUGU
CACGUdTdT-3′). Transfection was performed with Lipo-
fectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions.
Quantitative real-time PCR
RNA was extracted from the cells or tissues using TRIzol
(Invitrogen). miR-7 (qRT-PCR) reactions were performed
using Bulge-loop™ miRNA qRT-PCR Primer (RiboBio,
Guangzhou, China) and SYBR Green PCR Master Mix
(Applied Biosystems) according to the manufacturer’s
protocol. U6 was used for normalization. Relative gene ex-
pression was calculated by 2–ΔΔCt method.
Colony formation assay
Cells were plated onto 35 mm dishes (500 cells/well) in
DMEM culture. After 72 h of miR-7 mimic processing,
the cells were washed thrice with phosphate-buffered sa-
line (PBS), and fresh broth was supplied. After two
weeks, the cells were fixed in 3 mL of 4% paraformalde-
hyde for 30 min. Giemsa staining was performed for 20
min, and the cells were washed thrice with PBS. The
clone number was counted under a microscope.
Western blot
Cells processed for 48 h were collected, and protein was
extracted with lysis buffer containing phenylmethylsulfo-
nyl fluoride. Lysate was centrifuged at 14,000 rpm at 4°C
for 15 min, and protein content was measured using
bicinchoninic acid method. Up to 40 μg of proteins was
separated using 10% SDS–PAGE and transferred to poly-
vinylidene difluoride membrane. The membrane was in-
cubated with primary antibodies overnight at 4°C and
with secondary antibodies for 2 h at 25°C. The following
Figure 2 miR-7 suppresses glioma cellsgrowth and glycometabolismi
qRT-PCR in bothU87 cells and U251 cells. (B, C) Colony formation assay wa
activity and maximum glycolytic capacity was determined in real-time usin
calculated for two hours. ECAR following the addition of glucose defines g
glycolytic capacity. Each data point represents the mean ± SD of three exp
Figure 1 Clinical significance of miR-7 in glioma cases and
normal brain tissues. AveragemiR-7 expression in glioma cases
(n =480) and normal (n =10) tissues by microarray. **p <0.01.
Wang et al. Diagnostic Pathology 2014, 19:211 Page 3 of 6
http://www.diagnosticpathology.org/content/19/1/211antibodies were used: IGF-1R (1:1000, CST, USA), p-Akt
(1:1000, CST, USA), and Akt (1:1000, CST, USA). β-
actin (1:1000, CST, USA) was used as an internal protein
control.Luciferase reporter assays
IGF-1R 3′-untranslated region (UTR)-Luc reporter assay
was performed by ligating the IGF-1R 3′-UTR PCR prod-
uct into the XbaI site of the pGL3 control vector (Invitro-
gen). The mutant-type reporter was generated by deleting
the binding site of miR-7 “GUCUUCC.” The cells were
co-transfected with wild-type (pGL3-WT-IGF-1R-3′-
UTR) or mutant-type (pGL3-MUT-IGF-1R-3′-UTR) lu-
ciferase reports and miR-7 mimic or miR-NC. After 48
h of incubation, luciferase activity was measured using
the Dual Luciferase Reporter Assay System (Promega,
Madison, USA).n vitro. (A) The expression levels of miR-7 were determined by
s used to detect the colony formation activity. (D, E) The glycolytic
g the Seahorse extracellular flux analyzer. ECAR were continuously
lycolysis and ECAR following oligomycin represents maximum
eriments. *p <0.05, **p <0.01.
Figure 3 IGF-1R is a direct target of miR-7 in glioma cells.
(A) Diagram of seed sequence of miR-7 matched the 3′UTR of the
IGF-1R gene. (B) Luciferase reporter assays in glioma cells, following
co-transfection of cells with wild-type or mutant 3′UTR IGF1R and
miRNA, as indicated. (C) Effect of miR-7 on IGF-1R, AKT, pAKT protein
levels. Each data point represents the mean ± SD of three experiments.
**p <0.01.
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Glycolysis and glycolytic capacities were determined for
U87 and U251 cells using the Seahorse Extracellular
Flux (XF-96) analyzer (Seahorse Bioscience, Billerica,
MA) [22]. Cells were seeded in XF96-well plates and in-
cubated at 37°C in a 5% CO2 humidified atmosphere for
24 h. Extracellular acidification rates (ECARs) were
simultaneously measured real time after 1 d in XF-96.
Initially, the cells were incubated in the glycolysis stress
test medium without glucose, and ECARs were assessed.
Three sequential injections of D-glucose (10 mM), oli-
gomycin (1 μM), and 2-deoxyglucose (100 mM) were
injected in turn, and ECARs were assessed. Non-
glycolytic acidification was defined as initial and final
ECARs. Glycolysis was defined as ECAR following
addition of D-glucose and maximum glycolytic capacity,
which was defined as ECAR following addition of
oligomycin.
Statistical analysis
All experiments were performed in triplicate. Data were
expressed as mean ± SD. ANOVA and Student’s t-test,
which were based on SPSS 16.0 software, were used to
analyze the statistical differences. A two-sided P <0.05
was considered statistically significant.
Results
miR-7 expression and function in glioma cells in vitro
In TCGA database, the miR-7 expression in the GBM
group was significantly lower than that in the normal
brain tissue group (Figure 1). To identify the effects of
miR-7 on glioma cells, we conducted the following func-
tional assays. First, the miR-7 expression level in the
cells transfected with miR-7 mimics was determined by
real-time PCR (Figure 2A). Cell tablet assays revealed
that miR-7 overexpression can significantly inhibit the
number of colonies (Figure 2B and C). To assess the
function of miR-7 in glucose metabolism, we performed
a glycolysis stress test. Upregulation of miR-7 weakened
the glycolysis and glycolytic abilities of glioma cells com-
pared with those of the control (Figure 2D and E).
IGF-1R as a direct target of miR-7
To further clarify the molecular mechanisms of miR-7
in tumor suppression, we used a target prediction pro-
gram, TargetScan, to predict the putative targets of
miR-7. The 3′-UTR of IGF-1R mRNA contained a com-
plementary site for miR-7 (Figure 3A). Luciferase activ-
ity assays were conducted to confirm whether IGF-1R
is a putative target of miR-7. The wild- or mutant-type
luciferase reporter plasmids were constructed and co-
transfected with miR-7 mimics or scrambled into gli-
oma cells. Reporter assay results revealed that miR-7
overexpression led to a significant decrease in theluciferase activity of pGL3-WT-IGF-1R without chan-
ging that of pGL3-MUT-IGF-1R 3′-UTR (Figure 3B).
Accordingly, Western blot analysis showed that the
levels of IGF-1R and its downstream molecular events
decreased after transfection of miR-7 compared with
those in the miR-NC group (Figure 3B). Thus, miR-7
could directly regulate the IGF-1R/Akt signaling path-
way in glioma cells.
IGF-1R downregulation inhibits glioma cell growth and
glycometabolism in vitro
We performed the following functional assays to explore
the function of IGF-1R in cellular growth and meta-
bolism. Western blot was used to identify the downregu-
lation of IGF-1R by siRNA (Figure 4D). Similar to the
treatment with miR-7, the ability of colony formation
and glucose metabolism decreased after IGF-1R inhib-
ition (Figure 4A, B, and C). As expected, the activity of
AKT signaling was suppressed by si-IGF-1R (Figure 4D).
Discussion
Recent studies have focused on molecular factors, which
serve a function in carcinoma development. Thus, as a
prospective consequence, novel treatment strategies tar-
geting these factors and their receptors have been im-
proved. The IGF signaling axis is among the major
target themes of many studies searching for new strat-
egies in tumor treatment. The IGF signaling axis com-
prises three growth factors (IGF-1, IGF-2, and insulin),
three membrane receptors (IGF-1R, IGF-2R, and IR), six
Figure 4 IGF1R impact growth and glycometabolism of glioma cells. (D) IGF-1R, AKT, pAKT protein levels in U87 cells and U251 cells transfected
with siIGF1R were assessed by Western blot. (A, B, C). Representative cartogram showing proliferation and glycometabolism regulated by siIGF-1R. Each
data point represents the mean ± SD of three experiments. *p <0.05, **p <0.01.
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and proteases that modulate ligand availability [23,24].
IGF-1R serves many important functions in various
pathways of mitogenesis, angiogenesis, transformation,
apoptosis, and cell motility [25]. IGF-1Rs also interfere
with mitogenic and antiapoptotic events in malignant
cells. Thus, IGF-1R serves a potential function in car-
cinogenesis. Activated phosphorylated IGF-1R recruits
and activates signaling adaptor proteins, including IRS-
I, IRS-2, and Shc [26]. IRS phosphorylation activates
the phosphoinositide-3-kinase/Akt pathway, thereby
resulting in the synthesis of membrane-associated
phosphatidylinositol (3, 4, 5)-trisphosphate. Conse-
quently, Akt and protein kinase B are activated. Akt is
a kinase-activating molecule that induces antiapoptotic
proteins [27]. As a result of this signaling, many IGF-
1R effects are mediated, including mitogenesis, prolifer-
ation, cell-cycle control, and inhibition of apoptosis
[28]. We examined the mechanisms underlying the loss
of IGF-1R-inhibited cellular growth and metabolism
through the Akt pathway in glioma cells. Downregula-
tion of IGF-1R inhibited the activity of Akt and sup-
pressed cellular growth and metabolism.
Dysregulation of miRNA sequences is a common fea-
ture in human cancers, including glioma. miRNA is a
small non-coding single-stranded RNA comprising 21 nu-
cleotides to 25 nucleotides and regulates the expression of
target genes by interacting with specific sites onmessenger RNA, thereby repressing protein translation.
miRNA sequences have important regulatory functions in
basic biological processes, such as development, cellular
differentiation, proliferation, and apoptosis. Altered
miRNA regulation is involved in glioma pathogenesis via
oncogene and tumor suppressor modulation, which sub-
sequently affects downstream signaling pathways [29-31].
Consistent with previous reports, miR-7 was downregu-
lated in human glioma tissues in the current study [17].
Upregulation of miR-7 inhibited cellular growth and glu-
cose metabolism. Bioinformatics analysis results indicated
that IGF-1R could be a target of miR-7. Western blot and
luciferase reporter assays showed that miR-7 modulated
IGF-1R expression by directly targeting the binding site
within the 3′-UTR.
Conclusion
This study provides the first evidence that miR-7, as a
regulator of AKT pathway, serves a critical function in
cellular growth and glucose metabolism by directly tar-
geting IGF-1R. Therefore, miR-7 is a promising molecu-
lar drug for glioma treatment.
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